Breast Neoplasms trials recruiting in Massachusetts

All Breast Neoplasms trials nationally

Cities in Massachusetts

Recruiting trials in Massachusetts

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
  NCT04641247 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · Massachusetts: Boston
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of LY4257496 in Participants With Cancer (OMNIRAY)
  NCT07114601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
  NCT07213791 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  NCT06312176 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston, Worcester
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
  NCT07222215 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
  NCT07173751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Burlington
• Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
  NCT07214532 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
  NCT05386108 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
  NCT06686394 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston